Moderna Inc. ($MRNA) Stock Forecast: Up 11.9% Today

What is Moderna Inc.?

Moderna (MRNA) is a biotechnology company recognized for its innovative mRNA technology in vaccine development. Today, the stock showed a significant increase.

Why is Moderna Inc. going up?

MRNA stock is up 11.9% on Jan 6, 2026 17:45

• The rise in Moderna's stock today is linked to encouraging developments related to the company's vaccine technology:
• Funding from CEPI for a pivotal Phase 3 trial on Moderna's mRNA-based H5 pandemic influenza vaccine candidate indicates strong belief in the company's technology and its potential for global pandemic preparedness.
• Regulatory submissions for Moderna's seasonal influenza vaccine, mRNA-1010, in various countries, backed by favorable Phase 3 study results, underscore the company's dedication to broadening its vaccine range and addressing public health requirements.
• Moderna's focus on using mRNA technology to better align with changing flu strains and its dedication to keeping vaccine prices reasonable and ensuring equal access for lowto middle-income nations further increases investor confidence in the company's growth prospects.
• Positive clinical trial outcomes, advancements in regulatory processes, and strategic moves in vaccine creation collectively position Moderna as a significant player in the healthcare industry, boosting investor confidence and contributing to today's bullish market activity.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate

The Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $54.3 million to support a pivotal Phase 3 clinical trial for Moderna’s mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018. This funding aims to accelerate the vaccine's licensure and enhance global pandemic preparedness, potentially enabling rapid and equitable access to an H5 vaccine. If licensed, Moderna commits to allocating 20% of its H5 pandemic vaccine manufacturing capacity for timely supply to low- and middle-income countries at affordable pricing.

https://www.mycentraljersey.com/press-release/story/342884/cepi-to-fund-pivotal-phase-3-trial-for-modernas-mrna-pandemic-influenza-vaccine-candidate/

Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine

Moderna has submitted regulatory applications for its seasonal influenza vaccine candidate, mRNA-1010, for adults aged 50 and older to authorities in the U.S., EU, Canada, and Australia. These submissions are supported by positive Phase 3 study data showing the vaccine's efficacy and favorable safety profile. The company highlights that mRNA technology offers the potential to better match evolving flu strains, enhancing public health protection and supporting Moderna's future growth.

https://www.ydr.com/press-release/story/13306/moderna-announces-global-regulatory-submissions-for-its-investigational-seasonal-influenza-vaccine/

Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine

Moderna has filed for marketing authorization for its investigational seasonal influenza vaccine, mRNA-1010, in the U.S., EU, Canada, and Australia for adults aged 50 and older. The regulatory submissions are based on positive Phase 3 study data showing the vaccine achieved significant relative vaccine efficacy and was well-tolerated with a favorable safety profile. Moderna aims to leverage mRNA technology's agility to better match evolving flu strains, supporting the company's growth.

https://www.kitsapsun.com/press-release/story/696559/moderna-announces-global-regulatory-submissions-for-its-investigational-seasonal-influenza-vaccine/

Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine

Moderna has submitted its investigational seasonal influenza vaccine, mRNA-1010, for regulatory authorization in the U.S., EU, Canada, and Australia. The company highlights the potential of mRNA technology to address vaccine mismatch due to virus mutations and respond more effectively to evolving influenza strains. Positive data from Phase 3 studies support the applications, showing significant relative vaccine efficacy and a favorable safety profile for adults aged 50 and older.

https://www.citizen-times.com/press-release/story/42873/moderna-announces-global-regulatory-submissions-for-its-investigational-seasonal-influenza-vaccine/

Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine

Moderna has submitted regulatory applications for its investigational seasonal influenza vaccine, mRNA-1010, for adults aged 50 and older to authorities in the U.S., EU, Canada, and Australia. The company highlights that the vaccine achieved a relative vaccine efficacy of 26.6% in a Phase 3 study and demonstrated a favorable safety profile. These submissions represent a significant milestone for Moderna's respiratory portfolio and could support future growth if approved.

https://www.blueridgenow.com/press-release/story/51055/moderna-announces-global-regulatory-submissions-for-its-investigational-seasonal-influenza-vaccine/

Trending Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.4% Today

GlobalFoundries Inc. ($GFS) Stock Forecast: Up 5.0% Today

Allstate Corporation (The) ($ALL) Stock Forecast: Up 1.2% Today

Moderna Inc. ($MRNA) Stock Forecast: Up 11.9% Today

CleanSpark Inc ($CLSK) Stock Forecast: Down 5.2% Today

Johnson Controls International plc ($JCI) Stock Forecast: Down 9.2% Today

Capri Holdings Limited ($CPRI) Stock Forecast: Up 3.1% Today

Dollar General Corporation ($DG) Stock Forecast: Up 6.6% Today

Microchip Technology Incorporated ($MCHP) Stock Forecast: Up 8.7% Today

NXP Semiconductors N.V. ($NXPI) Stock Forecast: Up 6.6% Today

Moderna Inc. Price History

05.11.2025 - MRNA Stock was up 7.9%

• Moderna's stock experienced a surge today after a significant study from France verified the safety and effectiveness of its COVID-19 vaccine, reassuring investors about the company's primary product.
• This upward momentum was also backed by the company surpassing its 20-day moving average, indicating a short-term uptrend and optimistic earnings estimate adjustments.
• Institutional engagement with Moderna showed a mixed picture, with one entity reducing its position notably, while another entity acquired a considerable number of shares in the second quarter.
• Overall, the encouraging developments concerning the COVID-19 vaccine efficacy and technical signals played a role in the strong bullish movement witnessed in Moderna's stock today.

05.11.2025 - MRNA Stock was up 6.3%

• Moderna's positive market movement is linked to its surpassing of the 20-day moving average, indicating a favorable short-term trend and capturing the attention of traders.
• While a decrease in the stake held by Skandinaviska Enskilda Banken AB publ initially raised some concerns, the sizeable acquisition of shares by Norges Bank, alongside optimistic earnings forecast adjustments, likely bolstered investor trust in the stock.
• Despite a year-over-year revenue decline, Moderna's quarterly earnings surpassing expectations might have reassured investors regarding the company's growth prospects, playing a role in the current market positivity.
• In summary, Moderna's stock appears to have been driven upwards today by a blend of technical strength, encouraging earnings projections, and institutional investments.

31.11.2025 - MRNA Stock was down 5.4%

• Moderna's stock experienced a bearish movement, closing down 2.38% in the recent trading session, underperforming the broader market indices.
• The significant layoffs in the biotech industry, including at Moderna, may have contributed to investor concerns about the company's future growth prospects.
• Despite the recent dip, Moderna has shown strong performance over the past month, outpacing the Medical sector, indicating potential volatility in response to market news and events.
• The upcoming Investor Event – Analyst Day hosted by Moderna could provide insights into the company's strategic direction, potentially impacting investor sentiment and stock movement in the near future.

06.00.2026 - MRNA Stock was up 11.9%

• The rise in Moderna's stock today is linked to encouraging developments related to the company's vaccine technology:
• Funding from CEPI for a pivotal Phase 3 trial on Moderna's mRNA-based H5 pandemic influenza vaccine candidate indicates strong belief in the company's technology and its potential for global pandemic preparedness.
• Regulatory submissions for Moderna's seasonal influenza vaccine, mRNA-1010, in various countries, backed by favorable Phase 3 study results, underscore the company's dedication to broadening its vaccine range and addressing public health requirements.
• Moderna's focus on using mRNA technology to better align with changing flu strains and its dedication to keeping vaccine prices reasonable and ensuring equal access for lowto middle-income nations further increases investor confidence in the company's growth prospects.
• Positive clinical trial outcomes, advancements in regulatory processes, and strategic moves in vaccine creation collectively position Moderna as a significant player in the healthcare industry, boosting investor confidence and contributing to today's bullish market activity.

17.11.2025 - MRNA Stock was up 5.5%

• Moderna's bullish movement can be attributed to its participation in the prestigious J.P. Morgan Healthcare Conference, where it showcased its advancements in mRNA technology and its commitment to making a positive impact.
• The positive news of the CHMP backing EU approval for Moderna's new COVID-19 vaccine, mNexspike, for individuals aged 12 and older, also contributed to the stock's upward momentum.
• Despite Pfizer's disappointing revenue outlook affecting its stock and dragging down shares of vaccine rivals like Moderna, the overall market sentiment towards Moderna seems to have been buoyed by its continuous innovation and progress in developing new vaccines and therapies.
• Moderna's announcement of dosing the first patient in a Phase 1/2 study of an investigational T-cell engager for multiple myeloma further showcased the company's diversification and expansion into new treatment areas, adding to investor optimism.

18.11.2025 - MRNA Stock was up 5.1%

• Moderna's stock surged as a French study confirmed the effectiveness of its COVID-19 vaccine, showcasing a significant reduction in COVID-19 deaths among vaccinated individuals.
• The anticipation surrounding Moderna's presentation at the J.P. Morgan Healthcare Conference also contributed to the bullish momentum, highlighting the company's continued advancements in the healthcare sector.
• The broader biotech sector's positive performance, driven by successful clinical data, new drug launches, and increased M&A activity, further boosted Moderna's stock price.
• Despite facing some analyst skepticism and insider selling, Moderna's stock managed to outperform, showcasing investor confidence in the company's growth prospects and its position in the biotech industry.

23.11.2025 - MRNA Stock was down 8.8%

• Moderna CEO's decision to retain expiring stock options and show confidence in the company's recovery may have unsettled investors, contributing to the bearish movement.
• Increased stake by prominent institutional investors such as Thrivent Financial for Lutherans could signal faith in Moderna's future, but a director selling a large number of shares might have alarmed other investors.
• The funding from CEPI for a Phase 3 trial of Moderna's mRNA pandemic influenza vaccine candidate might have been overshadowed by short-term worries, impacting the stock price negatively.
• While the positive news regarding Biogen's sustained benefits for ALS patients did not have a direct influence on Moderna, it could have shifted attention and investments away from Moderna, leading to a decline in its stock performance.

23.11.2025 - MRNA Stock was down 5.0%

• Institutional investor, Thrivent Financial for Lutherans, notably increased its stake in Moderna by 600.7% in the second quarter, signaling strong institutional interest. However, concerns arose among investors due to a director selling a substantial number of shares, potentially contributing to the bearish movement.
• There are positive signs for Moderna's pipeline with the news of CEPI funding a pivotal Phase 3 trial for the company's mRNA pandemic influenza vaccine candidate. Despite this, profit-taking and worries about market saturation for vaccines could be influencing market activity.
• GSK PLC's positive quarterly earnings and guidance may have diverted investor attention from Moderna, impacting MRNA's stock performance negatively.
• The absence of specific adverse developments related to Moderna suggests that the market's bearish movement may stem from broader market sentiment or sector rotation rather than company-specific factors.

19.11.2025 - MRNA Stock was up 5.0%

• Moderna's bullish movement today could be attributed to the positive investor sentiment following its participation in the 44th Annual J.P. Morgan Healthcare Conference, where it showcased its developments in mRNA medicine.
• The news of receiving funding from the Coalition for Epidemic Preparedness Innovations (CEPI) for its bird flu vaccine candidate might have also boosted investor confidence in Moderna's future prospects.
• Despite the muted revenues and growth concerns, the market seems to be focusing on the potential of Moderna's innovative approach to vaccine development, driving the bullish movement in the stock today.

06.00.2026 - MRNA Stock was up 6.0%

• Moderna's stock observed a positive uptrend today due to encouraging updates on the company's vaccine progress and submissions for its seasonal influenza vaccine candidates.
• The recent funding from CEPI for a crucial Phase 3 trial on Moderna's mRNA-based H5 pandemic influenza vaccine reflects a strong vote of confidence in the company's technology and its potential role in global pandemic readiness.
• Regulatory filings for Moderna's mRNA-1010 seasonal influenza vaccine in significant markets like the U.S., EU, Canada, and Australia, supported by favorable Phase 3 trial results, have boosted investor confidence in the company's future growth prospects.
• Moderna's confirmed revenue outlook and forthcoming milestones, including the launch of multiple vaccines post-COVID-19, signal a solid long-term strategy that has resonated well with investors, underpinning the optimistic market sentiment towards the stock.

24.11.2025 - MRNA Stock was down 5.7%

• Moderna’s stock saw a decline to approximately $32.29 after a surge in late December. Several factors contributed to this movement:
• Investor worries regarding bird flu funding from CEPI and the progress of Moderna's mNEXSPIKE vaccine evaluated by the European Medicines Agency.
• Scrutiny on the company's financial moves, which include securing a $1.5 billion loan and outlining 2026 growth targets.
• Analysts have an overall "Hold" consensus rating with an average 12-month target price of $33.25, reflecting a cautious stance on the stock.
• The recent uptick in Moderna’s stock was primarily due to enhanced liquidity and cost containment rather than fundamental business growth, leading some investors to sell and reap profits. The decision aligns with concerns about declining fundamentals, like terminating the CMV program, which could impact the company's future prospects and pipeline.
• Today's bearish movement in Moderna’s stock seems to stem from profit-taking post a recent rally, investor focus on key developments and funding, and uncertainties about the company’s strategic path amidst evolving market trends.

04.11.2025 - MRNA Stock was up 5.2%

• Moderna's stock has surpassed its 20-day moving average, indicating a short-term bullish trend that has caught traders' attention.
• Institutional activity surrounding Moderna has been a mix, with one entity reducing its stake significantly as another acquired a substantial number of shares.
• Analyst opinions on Moderna vary, with some recommending a "Hold" position, but the overall sentiment is positive due to strong earnings estimates.
• The increase in Moderna's stock price could be due to technical strength from crossing the moving average and favorable fundamental factors like earnings outlook, despite varying institutional investor actions.